Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 3/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25263932 | 0.96 | MEN1 (0.58) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL7596881 | 0.93 | MEN1 (0.72) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL15460111 | 0.93 | MEN1 (0.68) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL5044911 | 0.93 | MEN1 (0.72) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL2367702 | 0.85 | MEN1 (0.59) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL7263741 | 0.85 | MEN1 (0.59) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL171304 | 0.85 | MEN1 (0.59) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL3806558 | 0.85 | MEN1 (0.61) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL1813642 | 0.85 | MEN1 (0.73) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL7363974 | 0.85 | MEN1 (0.58) | MEN1KMT2AKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042855-A1 | PERIPHERALLY AND LUMINALLY-RESTRICTED INHIBITORS OF THE SEROTONIN TRANSPORTER AS TREATMENTS FOR DISORDERS OF GASTROINTESTINAL MOTILITY AND GUT-BRAIN AXIS | THE JOHNS HOPKINS UNIVERSITY | 2025-02-06 | — | — | US | disclosed |
| WO-2023102477-A1 | PERIPHERALLY AND LUMINALLY-RESTRICTED INHIBITORS OF THE SEROTONIN TRANSPORTER AS TREATMENTS FOR DISORDERS OF GASTROINTESTINAL MOTILITY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023102477-A1 | PERIPHERALLY AND LUMINALLY-RESTRICTED INHIBITORS OF THE SEROTONIN TRANSPORTER AS TREATMENTS FOR DISORDERS OF GASTROINTESTINAL MOTILITY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-2321279-B1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | PIRAMAL IMAGING SA (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-20110200535-A1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2321279-A1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010015387-A1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015340-A1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042855-A1 | PERIPHERALLY AND LUMINALLY-RESTRICTED INHIBITORS OF THE SEROTONIN TRANSPORTER AS TREATMENTS FOR DISORDERS OF GASTROINTESTINAL MOTILITY AND GUT-BRAIN AXIS | SLC6A4, HTR6, HTR5A | MEN1 997/4885KMT2A 3009/4885KDM4C 4316/4885 |
| US-20110200535-A1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | GABRA6, GABRA4, GABRA1 | MEN1 1074/4885KMT2A 702/4885KDM4C 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.